Articles citing this paper
Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme
Jane Robertson, Emily J Walkom and David A Henry
33(2) pp.192 - 199
18 articles found in Crossref database.
Managed entry agreements for pharmaceuticals in Australia
Vitry Agnes, Roughead Elizabeth
Health Policy. 2014 117(3). p.345
Access to new cancer medicines in Australia: dispelling the myths and informing a public debate
Vitry Agnes,
Mintzes Barbara, Lipworth Wendy
Journal of Pharmaceutical Policy and Practice. 2016 9(1).
Challenges and opportunities for pharmaceutical pricing and reimbursement policies
Vogler Sabine,
Zimmermann Nina,
Ferrario Alessandra,
Wirtz Veronika J, Babar Zaheer-Ud-Din
Journal of Pharmaceutical Policy and Practice. 2015 8(S1).
Rising cost of anticancer drugs in Australia
Karikios D. J.,
Schofield D.,
Salkeld G.,
Mann K. P.,
Trotman J., Stockler M. R.
Internal Medicine Journal. 2014 44(5). p.458
How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries
Vogler Sabine,
Paris Valérie,
Ferrario Alessandra,
Wirtz Veronika J.,
de Joncheere Kees,
Schneider Peter,
Pedersen Hanne Bak,
Dedet Guillaume, Babar Zaheer-Ud-Din
Applied Health Economics and Health Policy. 2017 15(3). p.307
Patient access schemes in Asia-pacific markets: current experience and future potential
Lu Christine Y,
Lupton Caitlin,
Rakowsky Shana,
Babar Zaheer-Ud-Din,
Ross-Degnan Dennis, Wagner Anita K
Journal of Pharmaceutical Policy and Practice. 2015 8(1).
Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
Verghese Naina R.,
Barrenetxea Jon,
Bhargava Yukti,
Agrawal Sagun, Finkelstein Eric Andrew
Journal of Market Access & Health Policy. 2019 7(1). p.1601060
Drug price transparency initiative: A scoping review
Ahmad Nur Sufiza,
Makmor-Bakry Mohd, Hatah Ernieda
Research in Social and Administrative Pharmacy. 2020 16(10). p.1359
Operations Research and Health Care Policy (2013)
The changing role of economic evaluation in valuing medical technologies
Rotter Jason S,
Foerster Douglas, Bridges John FP
Expert Review of Pharmacoeconomics & Outcomes Research. 2012 12(6). p.711
Consistency of new drug pricing in Korea: Bridging variations among personnel in price negotiations
Kwon Hye-Young, Kim Jinhyun
Health Policy. 2020 124(9). p.965
Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review
Ghijben Peter,
Gu Yuanyuan,
Lancsar Emily, Zavarsek Silva
PharmacoEconomics. 2018 36(3). p.323
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers
Adamski Jakub,
Godman Brian,
Ofierska-Sujkowska Gabriella,
Osińska Bogusława,
Herholz Harald,
Wendykowska Kamila,
Laius Ott,
Jan Saira,
Sermet Catherine,
Zara Corrine,
Kalaba Marija,
Gustafsson Roland,
Garuolienè Kristina,
Haycox Alan,
Garattini Silvio, Gustafsson Lars L
BMC Health Services Research. 2010 10(1).
Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia
de Graaff Barbara,
Yee Kwang Chien,
Clarke Philip, Palmer Andrew
Applied Health Economics and Health Policy. 2018 16(4). p.495
Is there variation in private payor payments to cancer surgeons? A cross-sectional study in the USA
Bongiovanni Tasce,
Kim Simon P,
Kim Anthony,
Killelea Brigid, Gross Cary P
BMJ Open. 2020 10(10). p.e035438
Impact of the Australia—US Free Trade Agreement on Australian Medicines Regulation and Prices
Faunce Thomas,
Bai Jimmy, Nguyen Duy
Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. 2010 7(1). p.18
Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
Vogler Sabine,
Vitry Agnes, Babar Zaheer-Ud-Din
The Lancet Oncology. 2016 17(1). p.39
CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA
Robinson Maxine F.,
Mihalopoulos Cathrine,
Merlin Tracy, Roughead Elizabeth
International Journal of Technology Assessment in Health Care. 2018 34(1). p.46
